|
|
HOUSTON , June 14, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
|
|
|
|
HOUSTON , June 12, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
|
|
|
|
HOUSTON , May 10, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company, has been awarded a $1.9 million grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in support of PLx’s novel formulation of
|
|
|
|
Former CFO of Mucinex Innovator, Adams Respiratory Therapeutics, Joins Company HOUSTON , May 02, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg
|
|
|
|
Former Publicis and Pfizer Sales and Operations Director to Manage Commercial Launch of Aspertec HOUSTON , May 01, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325
|
|
|
|
-- PLx to focus on commercialization of Aspertec -- HOUSTON , April 19, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products: Aspertec 325 mg and Aspertec 81 mg (referred to together as
|
|
|
|
HOUSTON, Feb. 14, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (PLx), a late-stage specialty pharmaceutical company developing next-generation nonsteroidal anti-inflammatory drugs and other pharmaceutical agents today announced that
|
|
|
|
NEW YORK and HOUSTON, Dec. 22, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ) and PLx Pharma Inc.
|
|
|
|
HOUSTON (January 4, 2016) – PLx Pharma Inc. (PLx), a privately-held, late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safer and more effective aspirin products, announces that Natasha Giordano has been appointed as ...
|
|
|
|
Relative contributions of local and systemic mechanisms of upper gastrointestinal (GI) injury following aspirin are unknown. Studies suggest that aspirin’s GI risk is age related and that gastroprotection may be needed at therapy initiation.
|
|
